Prostate cancer: Diagnosis and staging

Asian Journal of Andrology

Volumn 11, Issue 1, 2009, Pages 74-80

  Borley, Nigel ^a   Feneley, Mark R ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FREE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; TUMOR MARKER;

ACINAR CELL CARCINOMA; BIOPSY TECHNIQUE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; NEEDLE BIOPSY; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE PREDICTIVE VALUE; PREDICTION; PRIMARY TUMOR; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL; REPEAT BIOPSY; REPRODUCIBILITY; REVIEW; SAFETY; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPLATE GUIDED BIOPSY; TRANSRECTAL ULTRASONOGRAPHY; ULTRASOUND GUIDED TRANSPERINEAL BIOPSY; BIOPSY; BLOOD; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 69449105848     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2008.19     Document Type: Review

References (39)

1. Jewett HJ. Significance of the palpable prostatic nodule. J Am Med Assoc. 1956; 160: 838-9.
2. Stone NN, DeAntoni EP, Crawford ED. Screening for prostate cancer by digital rectal examination and prostate-specific antigen: Results of prostate cancer awareness week, 1989-1992. Urology 1994; 44: 18-25.
3. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45: 70-4.
4. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995; 273: 289-94.
5. Wang MC, Valenzuela LA, Murphy GM, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
6. Andriole G, Djavan B, Fleshner N, Schroder F. The case of prostate cancer screening with prostate-specific antigen. Eur Urol 2004; 5: 737-45.
7. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges. JAMA 1993; 270: 860-4.
8. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, et al. Validity of the prostate specific antigen test for prostate cancer screening: Followup study with a bank of 21 000 sera in Finland. J Urol 2001; 166: 2189-91.
9. Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995; 46: 666-71.
10. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, et al Comparison of prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994; 152: 2031-6.
11. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, et al. Estimation of prostate specific growth using serial prostatespecific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-8.
12. Lilja H, Christensson A, Dahlen U. Prostate specific antigen in serum occurs predominately in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25.
13. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Use of the percentage free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter trial. JAMA 1998; 279: 1542-7.
14. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, et al "BPSA" a specific molecular form of free prostate-specific antigen, is found predominately in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000; 55: 41-5.
15. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, et al Evaluation of prostate specific antigen for the early detection of prostate cancer in men with a total specific antigen range of 4.0 to 10.0 ng/mL. J Urol 2003; 170: 723-6.
16. Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, et al. Accuracy of digital rectal examination and ultrasonography in localising prostate cancer. J Urol 1994; 152; 1506-9.
17. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, et al. Evaluation of transrectal ultrasound in the diagnosis of prostate cancer. J Urol 1989; 142: 1008-10.
18. Tan N, Lane BR, Li J, Moussa AS, Soriano M, et al. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. J Urol 2008; 180: 1325-9; discussion 1329.
19. Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi- Galluzzi C, et al. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J Urol 2008; 179: 1746-50; discussion 1750.
20. Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT. Utility of extended pattern prostate biopsies for tumor localization: Pathologic correlations after radical prostatectomy. Cancer 2008; 113: 1559-65.
21. Megwalu II, Ferguson GG, Wei JT, Mouraviev V, Polascik TJ, et al. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008; 102: 546-50.
22. Merrick GS, Taubenslag W, Andreini H, Brammer S, Butler WM, et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 2008; 101: 1524-9.
23. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
24. Lefkowitz GK, Taneja SS, Brown J, Melamed J, Lepor H. Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168: 1415-8.
25. Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53: 351-5.
26. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss; 2002.
27. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8.
28. Yeun JS, Thng Ch, Tan PH, Khin LW, Phee SJ, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumour foci in men with prior negative transrectal ultrasound prostate. J Urol 2004; 171: 1482-6.
29. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phase-array coil MR imaging: Multivariate feature analysis. Radiology 1997; 2002: 697-702.
30. Wang L, Mullerad M, Chen HN, Eberhardt SC, Kattan MW, et al. Prostate cancer: Incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004; 232: 133-9.
31. Rifkin NM, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: Results of a multi-institutional cooperative trial. N Engl J Med 1990; 323: 621-6.
32. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002; 167: 528-34.
33. Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study. Lancet Oncol. 2008; 9: 850-6.
34. Harisinghani MG, Heesakkers RA, Adang EM, Jager GJ, Barentsz JO. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer: MRI with a lymph nodespecific contrast agent compared to pelvic lymph node dissection or CT. Eur Radiol 2004; 14: 1707-12.
35. Lattouf JB, Beri A, Jeschke S, Sega W, Leeb K, et al. Laparoscopic extended pelvic lymph node dissection for prostate cancer: Description of the surgical technique and initial results. Eur Urol 2007; 52: 1347-55.
36. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. Erratum in: CA Cancer J Clin 2005; 55: 259.
37. Lentil BC, McGowan DG, Dierich H. Technetium-99 m polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 197; 46: 543-8.
38. Nozaki T, Yasuda K, Akashi T, Fuse H. Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol 2008; 15: 516-9.
39. Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, et al. Detection of vertebral metastases: Comparison between MR imaging and bone scintigraphy. Radiographics 1991; 11: 219-32.